Phase I/Ib Study of Adoptive Cellular Therapy Using Autologous IL-21-Primed CD8+ Tumor Antigen-Specific T Cells in Combination With Utomilumab (PF-05082566) in Patients With Platinum Resistant Ovarian Cancer
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 15 May 2018
At a glance
- Drugs Utomilumab (Primary) ; Cyclophosphamide; Interleukin-2
- Indications Ovarian cancer
- Focus Adverse reactions
- 04 May 2018 Planned End Date changed from 1 Apr 2021 to 1 Jul 2021.
- 04 May 2018 Planned primary completion date changed from 1 Apr 2020 to 1 Jul 2020.
- 04 May 2018 Planned initiation date changed from 1 Apr 2018 to 1 Jul 2018.